Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12339803 | 0.86 | — | — | |
| SCHEMBL14411872 | 0.76 | — | — | |
| SCHEMBL12153366 | 0.75 | — | — | |
| SCHEMBL6354239 | 0.74 | — | — | |
| SCHEMBL13927925 | 0.73 | BRD4 (0.32) | TRIM24TRIM33 | |
| SCHEMBL12129012 | 0.70 | LMNA (0.34) | — | |
| SCHEMBL13242069 | 0.70 | DRD1 (0.48) | — | |
| SCHEMBL14337354 | 0.69 | — | — | |
| SCHEMBL22283835 | 0.68 | CYP1A2 (0.36) | — | |
| SCHEMBL13656771 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | PURDUE PHARMA L.P. | 2018-07-26 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-9926297-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9878991-B2 | TRPV1 antagonists including dihydroxy substituent and uses thereof | PURDUE PHARMA L.P. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9856252-B2 | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-01-02 | — | — | US | disclosed |
| US-20170240530-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9670183-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9663533-B2 | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-9643967-B2 | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | KO SOO S | 2007-12-27 | — | — | US | disclosed |
| US-7312336-B2 | Compounds with analgesic effect | ASTRAZENECA CANADA INC. (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312222-B2 | Heterocyclic piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-7176198-B2 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070010513-A1 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CXCR1, CCR5 | TRIM24 3687/4885TRIM33 4140/4885POLB 2536/4885 |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | HRH3, CHRM2, HCRTR2 | TRIM24 4796/4885TRIM33 4326/4885POLB 3925/4885 |
| US-20070299057-A9 | HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR3, CCR1, CCR4 | TRIM24 3340/4885TRIM33 1830/4885POLB 3047/4885 |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | MMP9, MMP1, MMP13 | TRIM24 2284/4885TRIM33 2792/4885POLB 2774/4885 |
| US-20180208575-A1 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF | TRPV1, TRPA1, TRPV5 | TRIM24 3027/4885TRIM33 3179/4885POLB 4876/4885 |
| US-20070010513-A1 | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists | HRH3, HRH4, CHRM1 | TRIM24 4748/4885TRIM33 4521/4885POLB 4646/4885 |
| US-11654147-B2 | ALK2 inhibitors and methods for inhibiting BMP signaling | BMPR2, BMP1, BMP2K | TRIM24 388/4885TRIM33 1896/4885POLB 2728/4885 |
| US-20170240530-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | TRIM24 1966/4885TRIM33 2570/4885POLB 2680/4885 |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | TRIM24 1966/4885TRIM33 2570/4885POLB 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.